XTLB
Income statement / Annual
Last year (2025), X.T.L. Biopharmaceuticals Ltd.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2025, X.T.L. Biopharmaceuticals Ltd.'s net income was -$6.97 M.
See X.T.L. Biopharmaceuticals Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$451.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$448.00 K
|
$0.00
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$3.00 K
|
$0.00
|
-$1.00 K
|
-$1.00 K
|
-$1.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0.01
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$28.00 K
|
$98.00 K
|
$31.00 K
|
$30.00 K
|
$30.00 K
|
$38.00 K
|
$35.00 K
|
$38.00 K
|
$43.00 K
|
$443.00 K
|
| General & Administrative Expenses |
$1.13 M
|
$1.87 M
|
$734.00 K
|
$850.00 K
|
$1.00 M
|
$910.00 K
|
$807.00 K
|
$755.00 K
|
$1.19 M
|
$1.26 M
|
| Selling & Marketing Expenses |
$0.00
|
$178.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$1.13 M
|
$2.05 M
|
$734.00 K
|
$850.00 K
|
$1.00 M
|
$910.00 K
|
$807.00 K
|
$755.00 K
|
$1.19 M
|
$1.26 M
|
| Other Expenses |
$531.00 K
|
$31.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$1.69 M
|
$2.18 M
|
$765.00 K
|
$880.00 K
|
$1.03 M
|
$948.00 K
|
$842.00 K
|
$793.00 K
|
$1.25 M
|
$1.71 M
|
| Cost And Expenses |
$1.69 M
|
$2.62 M
|
$765.00 K
|
$880.00 K
|
$1.03 M
|
$948.00 K
|
$842.00 K
|
$793.00 K
|
$1.25 M
|
$1.71 M
|
| Interest Income |
$60.00 K
|
$34.00 K
|
$41.00 K
|
$36.00 K
|
$8.00 K
|
$33.00 K
|
$93.00 K
|
$87.00 K
|
$16.00 K
|
$0.00
|
| Interest Expense |
$7.00 K
|
$86.00 K
|
$4.00 K
|
$11.00 K
|
$21.00 K
|
$17.00 K
|
$29.00 K
|
$7.00 K
|
$8.00 K
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$199.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
$842.00 K
|
$1.00 K
|
$1.00 K
|
$3.00 K
|
| EBITDA |
-$752.00 K |
-$930.00 K |
-$764.00 K |
-$879.00 K |
-$1.03 M |
-$947.00 K |
$0.00 |
-$792.00 K |
-$1.25 M |
-$1.71 M |
| EBITDA Ratio |
0
|
-2.06
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-4.82
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$929.00 K
|
$1.02 M
|
-$1.02 M
|
-$468.00 K
|
$1.47 M
|
-$2.01 M
|
$79.00 K
|
$4.42 M
|
$465.00 K
|
$16.00 K
|
| Income Before Tax |
-$759.00 K
|
-$1.16 M
|
-$1.78 M
|
-$1.35 M
|
$435.00 K
|
-$2.95 M
|
-$1.35 M
|
$2.99 M
|
-$781.00 K
|
-$2.55 M
|
| Income Before Tax Ratio |
0
|
-2.57
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
-$130.00 K
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$69.00 K
|
-$80.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$6.97 M
|
-$1.03 M
|
-$1.78 K
|
-$1.35 M
|
$435.00 K
|
-$782.00 K
|
-$1.35 M
|
$2.99 M
|
-$781.00 K
|
-$2.55 M
|
| Net Income Ratio |
0
|
-2.28
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-17 |
-2.4 |
-30 |
-4 |
1.28 |
-9.12 |
-4.16 |
9.28 |
-2.72 |
-14.88 |
| EPS Diluted |
-16 |
-2.4 |
-30 |
-4 |
1.12 |
-9.12 |
-4.16 |
9.28 |
-2.72 |
-14.88 |
| Weighted Average Shares Out |
$420.65 K
|
$420.65 K
|
$340.60 K
|
$340.68 K
|
$332.50 K
|
$321.38 K
|
$321.38 K
|
$321.38 K
|
$293.87 K
|
$171.27 K
|
| Weighted Average Shares Out Diluted |
$440.10 K
|
$440.10 K
|
$340.57 K
|
$340.57 K
|
$384.72 K
|
$321.38 K
|
$321.38 K
|
$321.38 K
|
$293.87 K
|
$171.27 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
